# A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

> **NCT03564509** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 620 (actual)

## Conditions studied

- Controlled Ovarian Stimulation

## Interventions

- **DRUG:** FE 999302 (1 μg) and follitropin delta
- **DRUG:** FE 999302 (2 μg) and follitropin delta
- **DRUG:** FE 999302 (4 μg) and follitropin delta
- **DRUG:** FE 999302 (8 μg) and follitropin delta
- **DRUG:** FE 999302 (12 μg) and follitropin delta
- **OTHER:** Placebo and follitropin delta

## Key facts

- **NCT ID:** NCT03564509
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-14
- **Primary completion:** 2019-10-21
- **Final completion:** 2020-01-08
- **Target enrollment:** 620 (ACTUAL)
- **Last updated:** 2023-08-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03564509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03564509, "A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.". Retrieved via AI Analytics 2026-09-23 from https://api.ai-analytics.org/clinical/NCT03564509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*